Inhibition of USP10 induces degradation of oncogenic FLT3.

Inhibition of USP10 induces degradation of oncogenic FLT3.
复制标题

DOI:
10.1038/nchembio.2486
复制
发表时间:
2017-12
影响因子:
14.8
通讯作者:
Buhrlage SJ
Buhrlage SJ
中科院分区:
生物学1区
文献类型:
--
作者:
Weisberg EL;Schauer NJ;Yang J;Lamberto I;Doherty L;Bhatt S;Nonami A;Meng C;Letai A;Wright R;Tiv H;Gokhale PC;Ritorto MS;De Cesare V;Trost M;Christodoulou A;Christie A;Weinstock DM;Adamia S;Stone R;Chauhan D;Anderson KC;Seo HS;Dhe-Paganon S;Sattler M;Gray NS;Griffin JD;Buhrlage SJ

文献摘要

参考文献

被引文献

相似文献

致癌性FLT 3激酶是急性髓性白血病(AML)的重要治疗靶点,但由于FLT 3表达的点突变或代偿性增加导致快速出现耐药性,因此对小分子激酶抑制剂的临床应答是短暂的。我们试图开发一种互补的药理学方法,通过鉴定负责从FLT 3裂解泛素的去泛素化酶(DUBs)的抑制剂,可以促进蛋白酶体介导的FLT 3降解。由于FLT 3的相关DUB未知,我们组装了大多数报道的小分子DUB抑制剂的集中文库,并进行了细胞表型筛选,以鉴定可诱导致癌FLT 3降解的化合物。随后的目标去卷积工作使我们能够将USP 10确定为稳定FLT 3所需的关键DUB。靶向USP 10在AML的FLT 3-ITD阳性临床前模型中显示出疗效,包括细胞系、原代患者标本和致癌FLT 3驱动的白血病小鼠模型。
Oncogenic FLT3 kinase is an important therapeutic target in acute myeloid leukemia (AML), however clinical responses to small molecule kinase inhibitors are short-lived due to rapid emergence of resistance as a consequence of point mutations or compensatory increases in FLT3 expression. We sought to develop a complementary pharmacological approach whereby proteasome-mediated FLT3 degradation could be promoted by identifying inhibitors of the deubiquitinating enzyme(s) (DUBs) responsible for cleaving ubiquitin from FLT3. As the relevant DUBs for FLT3 are not known, we assembled a focused library of most reported small molecule DUB inhibitors and performed a cellular phenotypic screen to identify compounds that could induce degradation of oncogenic FLT3. Subsequent target deconvolution efforts allowed us to identify USP10 as the critical DUB required to stabilize FLT3. Targeting USP10 showed efficacy in FLT3-ITD positive pre-clinical models of AML, including cell lines, primary patient specimens and mouse models of oncogenic FLT3-driven leukemia.
DOI: 10.1038/sj.leu.2400921
发表时间: 1998-03-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Lavagna-Sévenier, C;Marchetto, S;Rosnet, O
通讯作者: Rosnet, O
Beclin1 通过调节 USP10 和 USP13 的去泛素化活性来控制 p53 的水平。
DOI: 10.1016/j.cell.2011.08.037
发表时间: 2011-09-30
期刊: Cell
影响因子: 64.5
作者:
Liu J;Xia H;Kim M;Xu L;Li Y;Zhang L;Cai Y;Norberg HV;Zhang T;Furuya T;Jin M;Zhu Z;Wang H;Yu J;Li Y;Hao Y;Choi A;Ke H;Ma D;Yuan J
通讯作者: Yuan J
DOI: 10.1158/2159-8290.cd-13-0609
发表时间: 2014-03
期刊: Cancer discovery
影响因子: 28.2
作者:
Pan R;Hogdal LJ;Benito JM;Bucci D;Han L;Borthakur G;Cortes J;DeAngelo DJ;Debose L;Mu H;Döhner H;Gaidzik VI;Galinsky I;Golfman LS;Haferlach T;Harutyunyan KG;Hu J;Leverson JD;Marcucci G;Müschen M;Newman R;Park E;Ruvolo PP;Ruvolo V;Ryan J;Schindela S;Zweidler-McKay P;Stone RM;Kantarjian H;Andreeff M;Konopleva M;Letai AG
通讯作者: Letai AG
DOI: 10.1016/s1535-6108(03)00003-5
发表时间: 2003-02-01
期刊: CANCER CELL
影响因子: 50.3
作者:
Armstrong, SA;Kung, AL;Korsmeyer, SJ
通讯作者: Korsmeyer, SJ
DOI: 10.1242/jcs.090985
发表时间: 2012-01-15
影响因子: 4
作者:
Clague, Michael J.;Coulson, Judy M.;Urbe, Sylvie
通讯作者: Urbe, Sylvie